Is it cost-effective to use a test to decide which individuals with an intermediate cardiovascular disease risk would benefit from statin treatment?

International Journal of Cardiology

Volumn 176, Issue 3, 2014, Pages 980-987

  Burgers, L T ^a   Nauta, S T ^b   Deckers, J W ^b   Severens, J L ^a   Redekop, W K ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

cardiovascular disease; cost effectiveness; decision modelling; prevention; statins; test

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE; AGED; BLOOD; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; COST BENEFIT ANALYSIS; FEMALE; HUMAN; MALE; MIDDLE AGED; PATIENT SELECTION; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MARKOV CHAINS; MIDDLE AGED; PATIENT SELECTION; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 84908193568     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.08.134     Document Type: Article

References (42)

1. M. Nichols, N. Townsend, and R. Luengo-Fernandez European Cardiovascular Disease Statistics 2012 2012
2. F. Taylor, K. Ward, and T.H.M. Moore Statins for the primary prevention of cardiovascular disease Cochrane Database Syst Rev 2011 1 2011 [CD004816]
3. J.J. Brugts, T. Yetgin, and S.E. Hoeks The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials Br Med J 339 JUN 30 2009 b2376
4. J.P. Greving, F.L.J. Visseren, G.A. de Wit, and A. Algra Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis Br Med J 342 MAR 30 2011 d1672
5. K.M. Anderson, P.M. Odell, P.W.F. Wilson, and W.B. Kannel Cardiovascular-Disease Risk Profiles Am Heart J 121 1 JAN 1991 293 298
6. R.M. Conroy, K. Pyorala, and A.P. Fitzgerald Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project Eur Heart J 24 11 JUN 2003 987 1003
7. J. Perk, G. De Backer, and H. Gohlke European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) Eur Heart J 33 13 JUL 2012 1635-U130
8. J. Yeboah, R.L. McClelland, and T.S. Polonsky Comparison of Novel Risk Markers for Improvement in Cardiovascular Risk Assessment in Intermediate-Risk Individuals JAMA 308 8 AUG 22 2012 788 795
9. P. Greenland, and P.G. O'Malley When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk Arch Intern Med 165 21 Nov 28 2005 2454 2456
10. British Cardiovascular Intervention Society BCIS Audit Returns Adult Interventional Procedures http://www.bcis.org.uk/resources/585-BCIS-Audit-2010-data-version-14-10-2011-for-web.pdf 2012
11. P.M. Ridker, J.G. MacFadyen, and F.A. Fonseca Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) Circ Cardiovasc Qual Outcomes 2 6 2009 616 623
12. H.M. Colhoun, D.J. Betteridge, and P.N. Durrington Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 9435 Aug 21-27 2004 685 696
13. J. Shepherd, G.J. Blauw, and M.B. Murphy Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 9346 NOV 23 2002 1623 1630
14. M. Law, and A.R. Rudnicka Statin safety: A systematic review Am J Cardiol 97 8A APR 17 2006 52C 60C
15. Statistics Netherlands National mortality statistics 2010 [Available at:] http://statline.cbs.nl/StatWeb/publication/?DM=SLNL&PA=7052-95&D1=0,42-48&D2=1-2&D3=0,12-17&D4=41-42&HDR=G2,G1,G3&STB=T&VW=T 2012
16. I. Vaartjes, I. van Dis, D.E. Grobbee, and M.L. Bots The dynamics of mortality in follow-up time after an acute myocardial infarction, lower extremity arterial disease and ischemic stroke BMC Cardiovasc Disord 10 Nov 25 2010 57
17. P. Sandercock, E. Berge, and M. Dennis Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs Stroke 35 6 Jun 2004 1490 1497
18. Society for Cardiothoracic Surgery in Great Britain & Ireland Sixth national adult cardiac surgical database report 2008 Demonstrating quality 6 2008
19. M. Westwood, M. Al, and L. Burgers A systematic review and economic evaluation of new-generation computed tomography scanners for imaging in coronary artery disease and congenital heart disease: Somatom Definition Flash, Aquilion ONE, Brilliance iCT and Discovery CT750 HD 2012 [dg3]
20. M. Westwood, M. Al, and L. Burgers A systematic review and economic evaluation of new-generation computed tomography scanners for imaging in coronary artery disease and congenital heart disease: Somatom Definition Flash, Aquilion ONE, Brilliance iCT and Discovery CT750 HD Health Technol Assess 17 9 2013 1 243
21. J. Oostenbrink, C. Bouwmans, and M. Koopmanschap Guideline for costing research Methods and standardized prices for economic evaluations in health care 2003 Health Care Insurance Board
22. Purchasing Power Parities and exchange rate for OECD countries [Available at:] http://stats.oecd.org/Index.aspx?DataSetCode=SNA-TABLE4 2011 [Accessed January 15, 2011]
23. Statistics Netherlands Consumer price index [Available at:] http://statline.cbs.nl/StatWeb/publication/?VW=T&DM=SLNL&PA=71311ned&D1=a&D2=0&D3=12,25,38,51,64,77,90,103,116,129,142,155,168,181-220&HD=120217-1502&HDR=G1,T&STB=G2 2012 [2012]
24. The Dutch Healthcare Authority Tariff General practitioner care 2012 2011 [TB/CU-7023-01]
25. Pharmaceutical Advisory Committee. Z index. 2011
26. P.W. Serruys, F. Unger, and J.E. Sousa Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease N Engl J Med 344 15 Apr 12 2001 1117 1124
27. R. Soekhlal, L. Burgers, W. Redekop, and S. Tan Treatment costs of acute myocardial infarction in the Netherlands 2013
28. S. Klarenbach, B. Manns, and N. Pannu Economic evaluation of continuous renal replacement therapy in acute renal failure Int J Technol Assess Health Care 25 3 Jul 2009 331 338
29. W.H. Bagley, H. Yang, and K.H. Shah Rhabdomyolysis Intern Emerg Med 2 3 Oct 2007 210 218
30. P. Youman, K. Wilson, F. Harraf, and L. Kalra The economic burden of stroke in the United Kingdom Pharmacoeconomics 21 Suppl. 1 2003 43 50
31. P. Clarke, A. Gray, R. Legood, A. Briggs, and R. Holman The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65) Diabet Med 20 6 Jun 2003 442 450
32. S. Palmer, M. Schulper, and Z. Philips Acost-effectiveness model comparing alternative managementstrategies for the use of glycoproteinIIb/IIIaantagonists in non-st-elevationacutecoronary syndrome Report to the National Institute for Clinical Excellence. 2002 2012 [Available at: http://www.nice.org.uk/nicemedia/live/11469/32434/32434.pdf ]
33. J.S. Benner, J.C. Tierce, and C.M. Ballantyne Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy Pharmacoeconomics 22 Suppl. 3 2004 13 23
34. C.A. Jackevicius, M. Mamdani, and J.V. Tu Adherence with statin therapy in elderly patients with and without acute coronary syndromes JAMA 288 4 Jul 24-31 2002 462 467
35. P.N. Post, A.M. Stiggelbout, and P.P. Wakker The utility of health states after stroke: a systematic review of the literature Stroke 32 6 Jun 2001 1425 1429
36. B.J. van Kempen, S. Spronk, and M.T. Koller Comparative effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in asymptomatic individuals J Am Coll Cardiol 58 16 Oct 11 2011 1690 1701
37. I. van Dis, D. Kromhout, J.M. Geleijnse, J.M. Boer, and W.M. Verschuren Evaluation of cardiovascular risk predicted by different SCORE equations: the Netherlands as an example Eur J Cardiovasc Prev Rehabil 17 2 Apr 2010 244 249
38. D.W. Lee, P.J. Neumann, and J.A. Rizzo Understanding the medical and nonmedical value of diagnostic testing Value Health 13 2 Mar-Apr 2010 310 314
39. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) JAMA 288 23 Dec 18 2002 2998 3007
40. J.R. Downs, M. Clearfield, and S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 20 May 27 1998 1615 1622
41. R. Collins, J. Armitage, S. Parish, P. Sleigh, and R. Peto Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 9374 Jun 14 2003 2005 2016
42. P.S. Sever, N.R. Poulter, and B. Dahlof The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure Eur Heart J 29 4 Feb 2008 499 508